Loading...

PetMed Express, Inc.

PETSNASDAQ
Healthcare
Medical - Pharmaceuticals
$2.30
$0.010(0.44%)
U.S. Market opens in 11h 42m

PetMed Express, Inc. Fundamental Analysis

PetMed Express, Inc. (PETS) shows weak financial fundamentals with a PE ratio of -0.74, profit margin of -35.51%, and ROE of -1.22%. The company generates $0.2B in annual revenue with weak year-over-year growth of -17.19%.

Key Strengths

Cash Position55.70%
PEG Ratio-0.00

Areas of Concern

ROE-1.22%
Operating Margin-17.38%
Current Ratio0.89
We analyze PETS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -143.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-143.3/100

We analyze PETS's fundamental strength across five key dimensions:

Efficiency Score

Weak

PETS struggles to generate sufficient returns from assets.

ROA > 10%
-73.74%

Valuation Score

Excellent

PETS trades at attractive valuation levels.

PE < 25
-0.74
PEG Ratio < 2
-0.00

Growth Score

Moderate

PETS shows steady but slowing expansion.

Revenue Growth > 5%
-17.19%
EPS Growth > 10%
18.92%

Financial Health Score

Moderate

PETS shows balanced financial health with some risks.

Debt/Equity < 1
0.02
Current Ratio > 1
0.89

Profitability Score

Weak

PETS struggles to sustain strong margins.

ROE > 15%
-122.10%
Net Margin ≥ 15%
-35.51%
Positive Free Cash Flow
No

Key Financial Metrics

Is PETS Expensive or Cheap?

P/E Ratio

PETS trades at -0.74 times earnings. This suggests potential undervaluation.

-0.74

PEG Ratio

When adjusting for growth, PETS's PEG of -0.00 indicates potential undervaluation.

-0.00

Price to Book

The market values PetMed Express, Inc. at 1.46 times its book value. This may indicate undervaluation.

1.46

EV/EBITDA

Enterprise value stands at -1.55 times EBITDA. This is generally considered low.

-1.55

How Well Does PETS Make Money?

Net Profit Margin

For every $100 in sales, PetMed Express, Inc. keeps $-35.51 as profit after all expenses.

-35.51%

Operating Margin

Core operations generate -17.38 in profit for every $100 in revenue, before interest and taxes.

-17.38%

ROE

Management delivers $-1.22 in profit for every $100 of shareholder equity.

-1.22%

ROA

PetMed Express, Inc. generates $-73.74 in profit for every $100 in assets, demonstrating efficient asset deployment.

-73.74%

Following the Money - Real Cash Generation

Operating Cash Flow

PetMed Express, Inc. generates limited operating cash flow of $-16.95M, signaling weaker underlying cash strength.

$-16.95M

Free Cash Flow

PetMed Express, Inc. generates weak or negative free cash flow of $-23.35M, restricting financial flexibility.

$-23.35M

FCF Per Share

Each share generates $-1.09 in free cash annually.

$-1.09

FCF Yield

PETS converts -46.37% of its market value into free cash.

-46.37%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.74

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

1.46

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.27

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.02

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.89

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-1.22

vs 25 benchmark

ROA

Return on assets percentage

-0.74

vs 25 benchmark

ROCE

Return on capital employed

-0.96

vs 25 benchmark

How PETS Stacks Against Its Sector Peers

MetricPETS ValueSector AveragePerformance
P/E Ratio-0.7428.92 Better (Cheaper)
ROE-122.10%643.00% Weak
Net Margin-35.51%-45024.00% (disorted) Weak
Debt/Equity0.020.34 Strong (Low Leverage)
Current Ratio0.894.50 Weak Liquidity
ROA-73.74%-16474.00% (disorted) Weak

PETS outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews PetMed Express, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-22.27%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

-123.60%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-88.18%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ